These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 16493198

  • 1. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.
    de Boer NK, Reinisch W, Teml A, van Bodegraven AA, Schwab M, Lukas M, Ochsenkühn T, Petritsch W, Knoflach P, Almer S, van der Merwe SW, Herrlinger KR, Seiderer J, Vogelsang H, Mulder CJ, Dutch 6-TG working group.
    Digestion; 2006; 73(1):25-31. PubMed ID: 16493198
    [Abstract] [Full Text] [Related]

  • 2. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
    van Asseldonk DP, Seinen ML, de Boer NK, van Bodegraven AA, Mulder CJ.
    J Crohns Colitis; 2012 Feb; 6(1):95-101. PubMed ID: 22261533
    [Abstract] [Full Text] [Related]

  • 3. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine.
    Seiderer J, Zech CJ, Reinisch W, Lukas M, Diebold J, Wrba F, Teml A, Chalupna P, Stritesky J, Schoenberg SO, Schima W, Göke B, Ochsenkühn T.
    J Hepatol; 2005 Aug; 43(2):303-9. PubMed ID: 15964660
    [Abstract] [Full Text] [Related]

  • 4. Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study.
    Pavlidis P, Ansari A, Duley J, Oancea I, Florin T.
    Inflamm Bowel Dis; 2014 Dec; 20(12):2239-46. PubMed ID: 25230165
    [Abstract] [Full Text] [Related]

  • 5. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension.
    Ferlitsch A, Teml A, Reinisch W, Ulbrich G, Wrba F, Homoncik M, Gangl A, Peck-Radosavljevic M, Vogelsang H.
    Am J Gastroenterol; 2007 Nov; 102(11):2495-503. PubMed ID: 17894846
    [Abstract] [Full Text] [Related]

  • 6. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients.
    de Boer NK, Zondervan PE, Gilissen LP, den Hartog G, Westerveld BD, Derijks LJ, Bloemena E, Engels LG, van Bodegraven AA, Mulder CJ.
    Dig Liver Dis; 2008 Feb; 40(2):108-13. PubMed ID: 18083079
    [Abstract] [Full Text] [Related]

  • 7. The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease.
    van Asseldonk DP, Jharap B, Verheij J, den Hartog G, Westerveld DB, Becx MC, Russel MG, Engels LG, de Jong DJ, Witte BI, Mulder CJ, van Nieuwkerk CM, Bloemena E, de Boer NK, van Bodegraven AA.
    Inflamm Bowel Dis; 2016 Sep; 22(9):2112-20. PubMed ID: 27482972
    [Abstract] [Full Text] [Related]

  • 8. Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
    Bayoumy AB, van Liere ELSA, Simsek M, Warner B, Loganayagam A, Sanderson JD, Anderson S, Nolan J, de Boer NK, Mulder CJJ, Ansari A.
    BMC Gastroenterol; 2020 Sep 11; 20(1):296. PubMed ID: 32917155
    [Abstract] [Full Text] [Related]

  • 9. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease.
    Geller SA, Dubinsky MC, Poordad FF, Vasiliauskas EA, Cohen AH, Abreu MT, Tran T, Martin P, Vierling JM, Targan SR.
    Am J Surg Pathol; 2004 Sep 11; 28(9):1204-11. PubMed ID: 15316320
    [Abstract] [Full Text] [Related]

  • 10. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?
    Gilissen LP, Derijks LJ, Driessen A, Bos LP, Hooymans PM, Stockbrügger RW, Engels LG.
    Dig Liver Dis; 2007 Feb 11; 39(2):156-9. PubMed ID: 17188950
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review.
    Meijer B, Mulder CJ, Peters GJ, van Bodegraven AA, de Boer NK.
    World J Gastroenterol; 2016 Oct 28; 22(40):9012-9021. PubMed ID: 27833392
    [Abstract] [Full Text] [Related]

  • 12. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review.
    Gisbert JP, González-Lama Y, Maté J.
    Am J Gastroenterol; 2007 Jul 28; 102(7):1518-27. PubMed ID: 17391318
    [Abstract] [Full Text] [Related]

  • 13. Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review.
    Toksvang LN, Schmidt MS, Arup S, Larsen RH, Frandsen TL, Schmiegelow K, Rank CU.
    PLoS One; 2019 Jul 28; 14(5):e0212157. PubMed ID: 31125338
    [Abstract] [Full Text] [Related]

  • 14. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.
    Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF.
    Gastroenterology; 2003 Aug 28; 125(2):298-303. PubMed ID: 12891528
    [Abstract] [Full Text] [Related]

  • 15. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
    Derijks LJ, de Jong DJ, Gilissen LP, Engels LG, Hooymans PM, Jansen JB, Mulder CJ.
    Eur J Gastroenterol Hepatol; 2003 Jan 28; 15(1):63-7. PubMed ID: 12544696
    [Abstract] [Full Text] [Related]

  • 16. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.
    Musumba CO.
    Aliment Pharmacol Ther; 2013 Nov 28; 38(9):1025-37. PubMed ID: 24099468
    [Abstract] [Full Text] [Related]

  • 17. Why measure thiopurine methyltransferase activity? Direct administration of 6-thioguanine might be the alternative for 6-mercaptopurine or azathioprine.
    de Jong D, Mulder CJ, van Sorge AA.
    Gut; 2001 Dec 28; 49(6):874. PubMed ID: 11758505
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease.
    Qasim A, McDonald S, Sebastian S, McLoughlin R, Buckley M, O'Connor H, O'Morain C.
    Scand J Gastroenterol; 2007 Feb 28; 42(2):194-9. PubMed ID: 17327939
    [Abstract] [Full Text] [Related]

  • 19. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients.
    de Boer NK, Derijks LJ, Gilissen LP, Hommes DW, Engels LG, de-Boer SY, den Hartog G, Hooymans PM, Mäkelburg AB, Westerveld BD, Naber AH, Mulder CJ, de Jong DJ.
    World J Gastroenterol; 2005 Sep 21; 11(35):5540-4. PubMed ID: 16222751
    [Abstract] [Full Text] [Related]

  • 20. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
    Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA.
    Am J Gastroenterol; 2003 May 21; 98(5):1058-63. PubMed ID: 12809828
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.